Logo image
Back
Bootcamp during neoadjuvant chemotherapy for breast cancer: A randomized pilot trial
Journal article   Open access   Peer reviewed

Bootcamp during neoadjuvant chemotherapy for breast cancer: A randomized pilot trial

Roshni Rao, Veronica Cruz, David Euhus, Yan Peng, Amy Harker-Murray, Barbara B Haley, Hong Zhao and Xian Jin Xie
Breast Cancer: Basic and Clinical Research, Vol.6(1), pp.39-46
2012
DOI: 10.4137/BCBCR.S9221
PMCID: PMC3290117
PMID: 22399859
url
https://doi.org/10.4137/BCBCR.S9221View
Published (Version of record) Open Access

Abstract

INTRODUCTION: Exercise may improve cancer outcomes. Neoadjuvant chemotherapy (NC) for breast cancer provides a unique setting to evaluate intervention effects. Treatments leading to decreased post-neoadjuvant Ki-67 levels, smaller tumor size, and higher pathologic response are associated with improved survival and lower recurrence. This randomized, prospective pilot trial evaluates the feasibility of supervised exercise during NC for breast cancer.METHODS: Stage II-III, ER positive, cancer patients with BMI > 25 receiving NC were randomized to standard NC with supervised bootcamp (NC + BC) or NC alone. Ki-67, C-peptide, BMI, and tumor size were measured before chemotherapy and at time of surgery.RESULTS: There were no initial differences between groups in regards to tumor size, C-peptide, BMI, and Ki-67. The NC + BC (n = 5) group had a lower mean BMI at the conclusion of NC compared with those (n = 5) in the NC group (28.0 versus 35.8, P = 0.03). Final tumor size was 2.59 cm in the NC + BC group versus 3.16 cm for NC (P = 0.76) Mean Ki-67 for NC + BC was 7% versus 29% with NC (P = 0.14). C-peptide (ng/mL) was equivalent between the two groups (4.55 NC + BC versus 4.74 NC, P = 0.85).CONCLUSIONS: Adding a supervised exercise program to NC is feasible, decreases BMI, and may lead to lower Ki-67 levels and improved survival.

Details

Metrics

32 Record Views
43 Times Cited - Web of Science
Logo image